Image de Google Jackets
Vue normale Vue MARC vue ISBD

Improving access to kidney transplantation for highly sensitized patients: What is the role of IL-6 pathway blockade in desensitization protocols?

Par : Contributeur(s) : Type de matériel : TexteTexteLangue : français Détails de publication : 2022. Ressources en ligne : Abrégé : BackgroundDesensitization allows kidney transplantation for highly sensitized subjects. Due to the central role of IL-6 in immunological response, tocilizumab (a monoclonal antibody directed against the IL-6 receptor) could potentially improve the efficacy of desensitization.MethodsWe conducted a systematic review using the following MeSH terms in PubMed: tocilizumab, clazakizumab, interleukin-6 blockade, kidney transplantation, kidney graft, and desensitization.StudiesIL-6 plays a role in humoral response (plasma cell differentiation induced by T cells, IL-21 secretion) as well as in cellular response (differentiation of T cells to Th17 rather than Treg). In desensitization, tocilizumab was first studied as a second-line treatment after failure of standard-of-care (apheresis and rituximab ± IgIV). A recent study showed that tocilizumab monotherapy attenuated anti-HLA antibody levels, but not enough to allow transplantation. However, lymphocyte immunophenotyping showed that tocilizumab hindered B cell maturation. Tocilizumab could potentially therefore improve the long-term efficacy of desensitization, by limiting anti-HLA rebound and thus preventing antibody-mediated rejection. This hypothesis is supported by a recent study that used clazakizumab (a monoclonal antibody directed against IL-6) in combination with standard-of-care. In this study, clazakizumab was continued after kidney transplantation. The results were encouraging: 9/10 patients received a transplant, and 6 months post-transplant none of them had developed donor-specific antibodies.ConclusionIL-6 pathway blockade monotherapy fails to desensitize highly sensitized kidney transplant candidates. In combination with standard-of-care, it does not appear to significatively improve kidney allograft access (short-term efficacy) vs. standard-of-care only. However, it could improve the long-term prognosis of HLA-incompatible transplant by orienting the response toward a tolerogenic profile, by hindering B-cell maturation and thereby preventing DSA rebound after transplantation. This hypothesis requires confirmation in further studies.
Tags de cette bibliothèque : Pas de tags pour ce titre. Connectez-vous pour ajouter des tags.
Evaluations
    Classement moyen : 0.0 (0 votes)
Nous n'avons pas d'exemplaire de ce document

75

BackgroundDesensitization allows kidney transplantation for highly sensitized subjects. Due to the central role of IL-6 in immunological response, tocilizumab (a monoclonal antibody directed against the IL-6 receptor) could potentially improve the efficacy of desensitization.MethodsWe conducted a systematic review using the following MeSH terms in PubMed: tocilizumab, clazakizumab, interleukin-6 blockade, kidney transplantation, kidney graft, and desensitization.StudiesIL-6 plays a role in humoral response (plasma cell differentiation induced by T cells, IL-21 secretion) as well as in cellular response (differentiation of T cells to Th17 rather than Treg). In desensitization, tocilizumab was first studied as a second-line treatment after failure of standard-of-care (apheresis and rituximab ± IgIV). A recent study showed that tocilizumab monotherapy attenuated anti-HLA antibody levels, but not enough to allow transplantation. However, lymphocyte immunophenotyping showed that tocilizumab hindered B cell maturation. Tocilizumab could potentially therefore improve the long-term efficacy of desensitization, by limiting anti-HLA rebound and thus preventing antibody-mediated rejection. This hypothesis is supported by a recent study that used clazakizumab (a monoclonal antibody directed against IL-6) in combination with standard-of-care. In this study, clazakizumab was continued after kidney transplantation. The results were encouraging: 9/10 patients received a transplant, and 6 months post-transplant none of them had developed donor-specific antibodies.ConclusionIL-6 pathway blockade monotherapy fails to desensitize highly sensitized kidney transplant candidates. In combination with standard-of-care, it does not appear to significatively improve kidney allograft access (short-term efficacy) vs. standard-of-care only. However, it could improve the long-term prognosis of HLA-incompatible transplant by orienting the response toward a tolerogenic profile, by hindering B-cell maturation and thereby preventing DSA rebound after transplantation. This hypothesis requires confirmation in further studies.

PLUDOC

PLUDOC est la plateforme unique et centralisée de gestion des bibliothèques physiques et numériques de Guinée administré par le CEDUST. Elle est la plus grande base de données de ressources documentaires pour les Étudiants, Enseignants chercheurs et Chercheurs de Guinée.

Adresse

627 919 101/664 919 101

25 boulevard du commerce
Kaloum, Conakry, Guinée

Réseaux sociaux

Powered by Netsen Group @ 2025